Latest Ratios: P/E Ratio 0.8x · EV/EBITDA N/A · ROE N/A. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $406M | $421M | $395M | $408M | $562M | $1.7B | $866M | $330M | $318M | $476M | $619M |
| Enterprise Value | $11.7B | $11.7B | $12.5B | $12.5B | $12.8B | $14.1B | $12.1B | $14.1B | $13.7B | $13.8B | $15.6B |
| P/E Ratio → | 0.76 | 0.83 | — | — | 12.34 | 7.56 | 1.70 | — | — | — | — |
| P/S Ratio | 0.03 | 0.03 | 0.03 | 0.03 | 0.05 | 0.14 | 0.07 | 0.02 | 0.02 | 0.03 | 0.03 |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | 0.27 |
| P/FCF | 1.95 | 2.02 | 3.29 | — | — | — | 0.50 | — | — | 2.35 | 0.42 |
| P/OCF | 0.75 | 0.78 | 0.82 | 1.94 | 1.87 | — | 0.40 | 0.86 | 1.16 | 0.62 | 0.26 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.94 | 0.99 | 1.00 | 1.05 | 1.14 | 1.02 | 1.07 | 0.97 | 0.90 | 0.85 |
| EV / EBITDA | — | — | 13.14 | 9.08 | 10.10 | 7.66 | 7.73 | 12.44 | 17.86 | — | 400.64 |
| EV / EBIT | — | 7.37 | 14.78 | 14.42 | 17.85 | 11.00 | 21.07 | 15.68 | 15.38 | 64.01 | 14.44 |
| EV / FCF | — | 56.45 | 103.83 | — | — | — | 6.95 | — | — | 68.11 | 10.49 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 8.7% | 8.7% | 41.7% | 40.7% | 40.2% | 41.1% | 37.5% | 38.7% | 38.3% | 34.6% | 36.9% |
| Operating Margin | -79.4% | -79.4% | 4.3% | 7.7% | 6.7% | 11.3% | 9.6% | 4.9% | 1.5% | -12.2% | -4.7% |
| Net Profit Margin | 4.1% | 4.1% | -4.1% | -1.1% | 0.4% | 1.9% | 4.3% | -4.5% | -5.6% | -16.0% | -9.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | -232.3% | -49.5% |
| ROA | 3.7% | 3.7% | -3.6% | -0.9% | 0.3% | 1.5% | 3.2% | -3.7% | -4.7% | -12.5% | -7.1% |
| ROIC | -70.1% | -70.1% | 3.7% | 6.3% | 5.3% | 9.7% | 7.6% | 4.0% | 1.2% | -9.2% | -3.3% |
| ROCE | -87.3% | -87.3% | 4.5% | 7.7% | 6.5% | 10.8% | 8.5% | 4.9% | 1.5% | -11.0% | -4.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | 6.68 |
| Debt / EBITDA | — | — | 12.77 | 8.81 | 9.75 | 6.99 | 8.25 | 12.34 | 17.70 | — | 390.87 |
| Net Debt / Equity | — | — | — | — | — | — | — | — | — | — | 6.58 |
| Net Debt / EBITDA | — | — | 12.73 | 8.78 | 9.66 | 6.71 | 7.18 | 12.15 | 17.45 | — | 384.77 |
| Debt / FCF | — | 54.42 | 100.54 | — | — | — | 6.45 | — | — | 65.76 | 10.08 |
| Interest Coverage | 1.83 | 1.83 | 0.98 | 1.05 | 0.84 | 1.44 | 0.56 | 0.87 | 0.91 | 0.23 | 1.12 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.46 | 1.46 | 1.41 | 1.50 | 1.41 | 1.47 | 1.60 | 1.50 | 1.48 | 1.73 | 1.62 |
| Quick Ratio | 1.32 | 1.32 | 1.27 | 1.34 | 1.25 | 1.32 | 1.48 | 1.35 | 1.32 | 1.54 | 1.45 |
| Cash Ratio | 0.12 | 0.12 | 0.02 | 0.02 | 0.05 | 0.21 | 0.60 | 0.09 | 0.08 | 0.24 | 0.08 |
| Asset Turnover | — | 0.95 | 0.90 | 0.86 | 0.83 | 0.81 | 0.74 | 0.85 | 0.89 | 0.88 | 0.84 |
| Inventory Turnover | 35.41 | 35.41 | 22.25 | 22.59 | 20.69 | 20.52 | 22.01 | 22.88 | 21.74 | 22.63 | 24.24 |
| Days Sales Outstanding | — | 66.01 | 70.69 | 69.00 | 63.88 | 64.22 | 63.87 | 66.18 | 64.65 | 60.31 | 66.55 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 100.0% | 120.8% | — | — | 8.1% | 13.2% | 59.0% | — | — | — | — |
| FCF Yield | 51.2% | 49.4% | 30.4% | — | — | — | 200.7% | — | — | 42.6% | 240.6% |
| Buyback Yield | 0.5% | 0.5% | 0.3% | 1.0% | 1.4% | 0.3% | 0.1% | 0.3% | 0.3% | 1.1% | 1.0% |
| Total Shareholder Yield | 0.5% | 0.5% | 0.3% | 1.0% | 1.4% | 0.3% | 0.1% | 0.3% | 0.3% | 1.1% | 1.0% |
| Shares Outstanding | — | $135M | $132M | $130M | $130M | $131M | $117M | $114M | $113M | $112M | $111M |
Includes 30+ ratios · 27 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CYH stock.
Community Health Systems, Inc.'s current P/E ratio is 0.8x. The historical average is 23.1x.
Based on historical data, Community Health Systems, Inc. is trading at a P/E of 0.8x. Compare with industry peers and growth rates for a complete picture.
Community Health Systems, Inc. has 8.7% gross margin and -79.4% operating margin.
Key Metrics
Top Statement Risk
Negative equity and high leverage
Metrics are mathematically derived from official filings.
Extreme Valuation Discount Amid Structural Risks
CYH trades at a P/E of 0.80 and a P/S of 0.03, reflecting severe market skepticism about its ability to generate sustainable earnings and service its high debt load, as reported in recent financial statements.
The valuation multiples are far below peer averages, such as HCA's P/E of 15.44, suggesting the market is pricing in significant downside risks. The low P/E may be misleading because earnings are volatile and the company has negative equity, indicating that traditional valuation metrics may not be applicable. Investors should consider the forward EV/EBITDA of 10.33, which is also below the sector median, but the debt burden likely inflates the enterprise value, warranting a discount.
Volatile Margins Undermine Earnings Quality
CYH's gross margin swung from -134.6% in 2025Q4 to 96.6% in 2026Q1, a volatility that far exceeds stable peer margins like HCA's 41.5%, indicating potential non-recurring items or accounting adjustments, according to company filings.
The extreme margin volatility suggests that the company's core operational profitability is inconsistent and may be influenced by one-time events or acquisition accounting. The operating margin has generally been positive but low, ranging from 7.4% to 16.3%, and net margin has been negative in several quarters, pointing to a weak bottom line. This instability in margins makes it difficult to assess the true earning power of the business and raises questions about the sustainability of recent improvements.
Perilous Leverage Despite Asset Reduction
With a D/EBITDA ratio of 20.53 in 2026Q2 and negative stockholders' equity, CYH's leverage remains critically high, and interest coverage of 1.05 times suggests barely adequate debt service capacity, based on reported balance sheet and income data.
The company's leverage, as measured by D/EBITDA, has been volatile and extremely high in recent quarters, far exceeding the typical threshold of 4-5x for health care companies. The negative equity position indicates that cumulative losses have eroded capital, leaving the balance sheet vulnerable to any operational or financial shock. The interest coverage ratio has fluctuated significantly, at times falling near 1x, which raises concerns about the company's ability to meet interest obligations from operating earnings.
Adequate Current Ratio Masks Cash Volatility
While CYH maintains a current ratio above 1.4 and a quick ratio around 1.3, its cash balance has been highly volatile, ranging from $33M to $712M, and stood at just $149M in 2026Q2, as per balance sheet data.
The current and quick ratios appear stable on the surface, but the underlying cash position has been erratic, which may indicate challenges in cash management or timing of cash flows. The company's liquidity could be strained if cash inflows are disrupted, given the heavy debt load and potential covenant requirements. Investors should monitor the composition of current assets, as the reliance on receivables and inventory could affect short-term liquidity under stress.
P/E Ratio Misleading Amid Negative Equity
The P/E ratio of 0.80 is the most commonly misapplied metric to CYH because it does not reflect the company's negative equity and high leverage, which distort the traditional relationship between price and earnings, based on peer comparison and capital structure.
For a company with negative equity and substantial debt, the P/E ratio can be artificially low because earnings are being generated on a negative equity base, which is not sustainable. A more appropriate metric might be EV/EBITDA, which accounts for debt, but even that must be interpreted in the context of the company's weak cash flow generation. Analysts should focus on cash flow-based metrics like P/FCF, but even that is volatile and may not capture the true risk profile.